You are here

Europe

Lilly faces biosimilar rivals to osteoporosis drug Forsteo in Europe

Lilly faces biosimilar rivals to osteoporosis drug Forsteo in Europe

Pharmaforum

Flag link:

EMA and FDA Historically Agree on Just About Every New Drug Approval, but is That Slowly Changing?

EMA and FDA Historically Agree on Just About Every New Drug Approval, but is That Slowly Changing?

RAPS.org

Flag link:

Brexit's Disruptive Impact On U.K. And European Prescription Drug Market

Brexit's Disruptive Impact On U.K. And European Prescription Drug Market

Forbes

Flag link:

Janssen gets EC approval for two new indications of Imbruvica

Janssen gets EC approval for two new indications of Imbruvica

Pharmaceutical Business Review

Waldenström’s macroglobulinemia

chronic lymphocytic leukemia

Flag link:

Novartis’ Zolgensma Joins Growing List of Medicines to Lose Accelerated Assessment Status in EU

Novartis’ Zolgensma Joins Growing List of Medicines to Lose Accelerated Assessment Status in EU

RAPS.org

Flag link:

AbbVie's psoriasis launch Skyrizi hitting stride ahead of FDA's decision on upadacitinib

AbbVie's psoriasis launch Skyrizi hitting stride ahead of FDA's decision on upadacitinib

Fierce Pharma

rheumatoid arthritis

Flag link:

European VC Firm Medicxi Closes $448 Million Fund

European VC Firm Medicxi Closes $448 Million Fund

CP Wire

venture capital

Flag link:

Here's Why Pacific Biosciences Is Tumbling Today

Here's Why Pacific Biosciences Is Tumbling Today

Motley Fool

Pacific Biosciences

Flag link:

Alexion’s Soliris follow-up Ultomiris snares EU approval

Alexion’s Soliris follow-up Ultomiris snares EU approval

Pharmaforum

Flag link:

Roche closes on EU approval for Tecentriq in breast cancer

Roche closes on EU approval for Tecentriq in breast cancer

Pharmaforum

triple negative breast cancer

Flag link:

Amgen/UCB hit another Evenity hurdle, as European regulators fail to back the osteoporosis drug

Amgen/UCB hit another Evenity hurdle, as European regulators fail to back the osteoporosis drug

Endpoints

Flag link:

'It's a growth play': Catalent acquires Bristol-Myers' European launch pad, expanding global CDMO ops

'It's a growth play': Catalent acquires Bristol-Myers' European launch pad, expanding global CDMO ops

Endpoints

Bristol-Myers Squibb

Flag link:

AstraZeneca's Lynparza gets EU nod as first-line ovarian cancer maintenance treatment

AstraZeneca's Lynparza gets EU nod as first-line ovarian cancer maintenance treatment

Yahoo/Reuters

Flag link:

Bluebird sets $1.8M price tag for blood-disease gene therapy

Bluebird sets $1.8M price tag for blood-disease gene therapy

Biopharma Dive

beta thalassemia

Flag link:

5 Things You'll Want to Watch With GW Pharmaceuticals

5 Things You'll Want to Watch With GW Pharmaceuticals

Motley Fool

Flag link:

Germany's Stada buys six of GSK's consumer brands, eyes further deals

Germany's Stada buys six of GSK's consumer brands, eyes further deals

Yahoo/Reuters

consumer health

Flag link:

Bluebird Bio’s Gene Therapy for Blood Disease Wins European Approval

Bluebird Bio’s Gene Therapy for Blood Disease Wins European Approval

Xconomy

beta thalassemia

Flag link:

EMA imposes formal limit on Xeljanz prescription as regulators continue to review safety concerns

EMA imposes formal limit on Xeljanz prescription as regulators continue to review safety concerns

Endpoints

post-marketing studies

Flag link:

EU universities are miserably lax at reporting clinical trial results, analysis suggests

EU universities are miserably lax at reporting clinical trial results, analysis suggests

Endpoints

clinical trial data

clinical trials

Flag link:

Lynparza on cusp of EU approval for advanced ovarian cancer

Lynparza on cusp of EU approval for advanced ovarian cancer

Pharmaforum

Flag link:

Pages